Last reviewed · How we verify

Adlumiz — Competitive Intelligence Brief

Adlumiz (ANAMORELIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Growth hormone secretagogue receptor type 1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Adlumiz (ANAMORELIN) — ONO PHARMACEUTICAL Co., Ltd.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Adlumiz TARGET ANAMORELIN ONO PHARMACEUTICAL Co., Ltd marketed Growth hormone secretagogue receptor type 1
Macrilen MACIMORELIN Aeterna Zentaris marketed Growth Hormone Secretagogue Receptor Agonist Growth hormone secretagogue receptor type 1 2017-01-01
Capimorelin CAPROMORELIN marketed Growth hormone secretagogue receptor type 1, Growth hormone secretagogue receptor type 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adlumiz — Competitive Intelligence Brief. https://druglandscape.com/ci/anamorelin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: